GlassScriptPhysician profile
Alisha Solomon
NPI 1194169672
$9,639.92
in general payments reported to CMS, 2019-2025
57 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $752 · 2021: $2,120 · 2022: $1,681 · 2023: $1,475 · 2024: $1,391 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,104.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,296.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,076.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,054.40 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $801.21 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $697.12 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $684.76 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $457.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $338.61 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.18 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $223.35 | 2019-2023 | Vaxneuvance, Vaxelis, M-M-R II |
| Corium, LLC | $216.52 | 2022-2024 | Azstarys |
| Amgen INC. | $194.24 | 2019-2023 | Prolia, Evenity, Repatha |
| Biohaven Pharmaceuticals, INC. | $174.16 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.82 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $133.61 | 2021-2023 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.